KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Clover Health Investments (CLOV) EBITDA (2019 - 2025)

Clover Health Investments (CLOV) has disclosed EBITDA for 7 consecutive years, with $41.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 269.73% year-over-year to $41.6 million, compared with a TTM value of $7.5 million through Dec 2025, up 117.66%, and an annual FY2025 reading of $323.3 million, up 865.76% over the prior year.
  • EBITDA was $41.6 million for Q4 2025 at Clover Health Investments, up from -$24.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $41.6 million in Q4 2025 and bottomed at -$317.5 million in Q2 2021.
  • Average EBITDA over 5 years is -$58.9 million, with a median of -$37.3 million recorded in 2021.
  • The sharpest move saw EBITDA plummeted 6439.41% in 2021, then soared 269.73% in 2025.
  • Year by year, EBITDA stood at -$188.5 million in 2021, then surged by 55.77% to -$83.4 million in 2022, then increased by 18.72% to -$67.8 million in 2023, then skyrocketed by 63.81% to -$24.5 million in 2024, then skyrocketed by 269.73% to $41.6 million in 2025.
  • Business Quant data shows EBITDA for CLOV at $41.6 million in Q4 2025, -$24.1 million in Q3 2025, and -$10.3 million in Q2 2025.